A more excellent choice

Arete Therapeutics Inc. decided to switch gears and focus on developing its first-in-class oral soluble epoxide hydrolase inhibitor for Type II diabetes rather than hypertension based on a more robust antidiabetic profile in preclinical models. If the company succeeds, it could have a drug that controls glucose while providing renal and cardioprotection.

The company began a 28-day Phase IIa trial of AR9281 in 150 patients with impaired glucose tolerance and high

Read the full 701 word article

How to gain access

Continue reading with a
two-week free trial.